Thomas Armer

Thomas ArmerThomas A. Armer founded MAP Pharmaceuticals in 2003. MAP is a biopharmaceutical company focused on developing and commercializing new therapies in neurology. Tom was MAP’s first President and CEO, and became the Chief Scientific Officer in 2005. He was also a member of MAP’s Board of Directors. Tom led the development of LEVADEX®, an orally inhaled drug for the potential acute treatment of migraine in adults. LEVADEX® is currently under review with the U.S. Food and Drug Administration. MAP was acquired by Allergan in April 2013 and is operated as a wholly owned subsidiary of Allergan. Tom currently serves as CSO and VP of Inhalation Products at Allergan.

From 1998 to 2003, Tom served as Vice President of Pulmonary Delivery Systems and later as Chief Scientific Officer at Sheffield Pharmaceuticals, Inc., a biopharmaceutical company focused on development of pharmaceuticals for pulmonary delivery. From 1989 to 1998, Tom held a series of senior management and product development positions at the Novon Products Group, a division of Warner-Lambert, and Aeroquip Vickers Corporation. He started his career working in polymer research at Shell Development Company.

Tom received a B.S. in chemical engineering from New Mexico State in 1977. He also earned an M.S. and a Ph.D. in chemical engineering from Tulane in 1979 and 1982, respectively.

When not working, Tom enjoys endurance bicycling. He participates in a 100+ mile organized event at least monthly, and has sponsored the Miles for Migraine and the AIDs/Lifecycle events in California for the past 2 years. He is also actively involved in emergency preparedness, serving as a member of the Community Emergency Response Team in Mountain View, CA supporting operations as a first responder and as a licensed ham radio operator (KK6DZH).

Tom is married to fellow Tulanian Helen Armer (B.S. Engineering 1980). They have four children. They live in Los Altos, California.